Right now, no major purchase or licensing deal worth more than $50 million looks likely to close in the next eight weeks. Big institutional investors are sitting on their hands, waiting for hard clinical trial results before committing serious money. One company, CMPS, keeps lagging behind its rival MMED in stock performance because neither has announced a big Phase 3 trial result yet.
No catalyst in today's signals. Institutional capital waits for topline data; retail hype is absent from the tape.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →